A standard lipid panel — total cholesterol, LDL-C, HDL-C, triglycerides — was built to answer one question: is disease present right now? It's a good tool for that. It was never designed to answer a different question a lot of people are now asking earlier in life: where is my cardiovascular system trending over the next 20–40 years? That's a longer-horizon question, and it needs a slightly different panel.
Standard lab ranges are built to flag disease that has already developed. Longevity-optimal targets are stricter — they're the levels associated with the lowest lifetime cardiovascular risk, not just "not diagnosable yet." Both are valid; they're answering different questions. Nothing below replaces what your doctor already ordered — it's the fuller reference frame to read those same numbers against.
LDL-C measures the cholesterol mass inside your LDL particles. ApoB counts the particles themselves — one ApoB molecule per atherogenic particle (LDL, VLDL remnants, Lp(a)). In roughly 20–25% of people — especially with elevated triglycerides, insulin resistance, or metabolic syndrome — LDL-C and ApoB disagree, and when they do, ApoB tracks risk more closely.
| Risk category | ApoB target |
|---|---|
| Moderate risk | <100 mg/dL |
| High risk | <80 mg/dL |
| Very-high risk | <65 mg/dL |
Source: ESC/EAS 2019 Dyslipidaemia Guidelines (ehz455), secondary goal — reaffirmed unchanged in the 2025 Focused Update (ehaf190).
Lp(a) is genetically determined and largely unaffected by diet or exercise — which is exactly why it's worth measuring, once, in every adult. Unlike LDL-C, it doesn't move much over a lifetime, so a single result is usually enough to know where you stand.
| Lp(a) level | What it means |
|---|---|
| <75 nmol/L (<30 mg/dL) | Rule-out range |
| 75–125 nmol/L | Grey zone |
| ≥125 nmol/L (>50 mg/dL) | Clinically significant — consider family screening |
Source: EAS 2022 Lp(a) consensus statement (ehac361). No approved Lp(a)-lowering drug exists yet — pelacarsen and olpasiran remain investigational, with outcomes data expected through 2026.
High-sensitivity CRP flags inflammation that contributes to plaque activity independent of your cholesterol numbers. It's a modifier, not a stand-alone diagnosis — a persistently elevated value is a reason to look closer, not a treatment decision on its own.
| hs-CRP | What it means |
|---|---|
| <1 mg/L (ideally <0.5) | Longevity-optimal |
| 1–3 mg/L | Average |
| >3 mg/L, or >2 mg/L persistently | Risk modifier — ESC/EAS 2025 (ehaf190) |
Both of these are calculated, not separately drawn — they're derived from triglycerides, fasting glucose, and HDL-C, values most panels already include. They flag insulin resistance and plasma atherogenicity earlier than fasting glucose alone often does.
Full detail — including formulas and interpretation — lives in our Complete Guide to Cardiometabolic Health.
It's tempting to add every marker with a paper behind it. We hold a narrower line: a marker earns a place in a consumer report only if it's DOI-verified, tied to a named guideline or validated cohort, and calculable from data CardioIQ's panel already collects. Markers like SII, CRP/Albumin ratio, or FIB-4 didn't clear that bar for this panel — not because they're uninteresting, but because they require inputs CardioIQ doesn't measure, or rest on cutoffs that aren't yet guideline-established.
For a side-by-side of what a standard panel includes vs. what a fuller advanced panel adds, see our Standard vs. Advanced Lipid Panel guide.
Possibly — LDL-C and ApoB disagree in roughly 20–25% of people, most often with elevated triglycerides, insulin resistance, or metabolic syndrome. If any of those apply to you, ApoB gives a more complete picture.
Yes — it's genetically determined and largely fixed from early adulthood. That's why testing it once, and telling first-degree relatives if it's elevated, matters more than retesting it.
Lp(a): once, in most cases. ApoB, lipids, hs-CRP, and the metabolic indices: alongside your regular annual panel, or sooner if you've made a significant treatment or lifestyle change your physician wants to track.
Have any of these numbers already? The Optimal vs Normal check shows where they sit — against your lab's standard range and the longevity-optimal target a lipidologist works from.
See where my numbers sit — free →